Cynthia Ripple
Nurse Practitioner · Bath, NYNPI 1730117565
Payments from drug & device makers
Across 171 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$610
- AstraZeneca$511
- Lilly USA, LLC$304
- Pfizer$230
- Novo Nordisk$219
- Boehringer Ingelheim$214
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 28 | $610 |
| AstraZeneca | 23 | $511 |
| Lilly USA, LLC | 17 | $304 |
| Pfizer | 12 | $230 |
| Novo Nordisk | 11 | $219 |
| Boehringer Ingelheim | 10 | $214 |
| Abbott | 6 | $186 |
| GSK | 7 | $128 |
| Exact Sciences | 5 | $124 |
| Merck | 6 | $120 |
| Johnson & Johnson | 7 | $115 |
| Teva Pharmaceuticals USA, Inc. | 5 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $75 |
| Corcept Therapeutics | 3 | $52 |
| Bayer | 2 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Inogen, Inc. | 2 | $34 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| Novartis | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Astellas Pharma US Inc | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$3,478 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 12 | $143,501 |
| TrulicityDulaglutide | 75 | $96,682 |
| JardianceEmpagliflozin | 60 | $84,852 |
| XareltoRivaroxaban | 84 | $71,455 |
| VraylarCariprazine Hcl | 29 | $46,242 |
| EliquisApixaban | 45 | $41,534 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $30,332 |
| OzempicSemaglutide | 23 | $29,333 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $28,555 |
| MyrbetriqMirabegron | 24 | $28,111 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $25,295 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $23,967 |
| Spiriva RespimatTiotropium Bromide | 22 | $22,236 |
| JanuviaSitagliptin Phosphate | 12 | $19,031 |
| MounjaroTirzepatide | 13 | $15,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Qvar Redihaler | $90 | $146,90426 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $304 | $112,14588 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $214 | $107,08882 claims |
| Johnson & JohnsonXarelto | $115 | $71,45584 claims |
| AbbVieVraylar | $610 | $46,24229 claims |
| PfizerEliquis, Paxlovid | $230 | $45,57457 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $128 | $44,55783 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Brilinta | $511 | $43,81065 claims |
| Novo NordiskOzempic | $219 | $29,33323 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $28,11124 claims |
| MerckJanuvia | $120 | $19,03112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in Bath
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
- Kelly WilmarthJohnson City$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.